Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-masked, Multicenter, Laser-controlled Phase III Study Assessing the Efficacy and Safety of Ranibizumab (Intravitreal Injections) as Adjunctive and Mono-therapy in Patients With Visual Impairment Due to Diabetic Macular Edema

NCT00687804 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00687804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00687804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-masked, Multicenter, Laser-controlled Phase III Study Assessing the Efficacy and Safety of Ranibizumab (Intravitreal Injections) as Adjunctive and Mono-therapy in Patients With Visual Impairment Due to Diabetic Macular Edema
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2008
Completion date
January 31, 2012
Enrollment
345 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema